BACKGROUND AND MISSION
The Lilly Global Health Partnership was launched to serve global public health goals through innovative assistance that complements the traditional philanthropy of Lilly. The Lilly MDR-TB Partnership was created to help address the challenge of multi-drug resistant tuberculosis (MDR-TB), and the Lilly NCD Partnership to address the growing challenges caused by non-communicable diseases, in particular, diabetes in low-income countries. These partnerships aim to address critical gaps and find new models of care through high-level consultations and on the ground engagement.

AREAS OF INTEREST
- Training of health care workers, doctors and pharmacists
- Transfer of technology for manufacturing medicines in the countries they are needed
- Research for piloting health care models
- Data and knowledge sharing
- Advocating for data-proven, cost-effective health care solutions

HEALTH-RELATED ACTIVITIES
Lilly Global Health Partnership works in Brazil, China, India, Kenya, Mexico, Russia, South Africa and USA with nearly 50 global health partners. They focus on developing community-based healthcare models to improve access to care and health outcomes related to tuberculosis, diabetes and cancer in resource-limited settings. In the fight against MDR-TB, the partnership facilitated the technology transfer of manufacturing know-how to manufacturers in countries most affected by the disease, and continues to train health workforce and facilitate access to second-line medicines. To address NCDs, the partnership increases access to quality care and facilitates early diagnosis and proper treatment in communities with significant unmet needs in diabetes or cancer care.

GOVERNANCE AND STAFF
The partnership’s secretariat is located in the Geneva office of Eli Lilly and Company.

FUNDING SOURCES AND BUDGET
The partnership is supported by the Eli Lilly and Company Foundation and United Way Worldwide.
PUBLICATIONS
See: https://www.lilly.com/caring/improving-global-health

Last update: 21.08.2019